These findings demonstrated that EGFR is essential in the GPR30-mediated pathway and further support the notion that lapatinib, in combination with tamoxifen, may be used in patients with breast cancers for preventing the development of endometrial cancer [49]. Here, EGFR is linked to breast carcinoma.